Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Concerns about cardiotoxicity in the HERA trial – Authors’ reply

We would like to thank Antonin Levy and colleagues for their interest in our Article reporting the 11-year outcome data from the HERceptin Adjuvant (HERA) trial,1 and their expressed concern that we might not have recorded all long-term cardiac consequences of treatment for early breast cancer, specifically, some that could be secondary to the use of radiotherapy.